Galcanezumab
EMGALITY
Pronunciation: gal-ka-NEZ-yoo-mab (em-GAL-it-ee)
“Gal can zoom (for) Equality”
What it isCGRP ligand antibody; migraine and cluster headache prevention.
Why this oneThe only CGRP agent approved for episodic cluster headache.
What limits itInjection-site reactions; cost and access. Response takes weeks, so it cannot be judged after one dose.
FDA-approved for
- migraine prophylaxis (2018)
- episodic cluster headache (2019)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Migraine prevention | Adults | 240 mg loading, then 120 mg monthly | 120 mg monthly | |
| Episodic cluster headache | Adults | 300 mg monthly (at cluster onset until period ends) | 300 mg monthly |
Renal Undefined
Hepatic Undefined
Instructions
- Subcutaneous only — abdomen, thigh, back of upper arm, or buttocks
- Migraine loading dose given as two consecutive 120 mg injections; cluster dose as three consecutive 100 mg injections
Available strengths
- inj 100, 120 mg/mL
Cautions
- Hypersensitivity reactions (anaphylaxis, angioedema) — can occur days later and be prolonged
- Constipation with serious complications
- Hypertension (new-onset or worsening)
- Raynaud's phenomenon
Adverse reactions
- Injection site reactions
Pregnancy No adequate human data; no adverse developmental effects in animals
Lactation No human data
Cost
| Strength | #/mo | generic $/unit | brand $/unit | CostPlus | |
|---|---|---|---|---|---|
| 100 mg/mL | inj | per unit | — | $612.52/mL | not offered |
| 120 mg/mL | inj | per unit | — | $734.35/mL | not offered |
Generic entry2034 est. (biosimilar)
NO BOXED WARNINGS
Principal riskInjection-site reactions
Classes and tags
Clinical profile
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilityInjection reactions and hypersensitivity; acute overdose toxicity is low.
Open Galcanezumab in the interactive console ↗
Memory aids: interaction avatars
